Cigna earnings beat by $0.04, revenue topped estimates
IO Biotech , Inc. (NASDAQ:IOBT), a pharmaceutical company, disclosed the outcomes of its 2025 Annual Meeting of Stockholders held on Thursday, June 5, 2025. The filing with the Securities and Exchange Commission on Monday detailed the voting results on two proposals that were on the agenda.
The first item on the agenda was the election of a Class I director. David Smith was elected to the board with 40,444,898 votes in favor, 3,010,542 withheld, and 8,622,498 broker non-votes.
The second proposal was the ratification of EY Godkendt Revisionspartnerselskab as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. This motion passed with 51,581,966 votes for, 183,927 against, and 312,045 abstentions.
IO Biotech, headquartered in Copenhagen, Denmark, is incorporated in Delaware and is classified under the pharmaceutical preparations industry. The company’s common stock is traded on The Nasdaq Stock Market LLC under the symbol IOBT.
The press release also confirmed that IO Biotech is not an emerging growth company and has not elected to use the extended transition period for complying with new or revised financial accounting standards.
The information provided in this article is based on an SEC filing by IO Biotech, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.